Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
- Ono Files NDA for Nivolumab for Malignant Melanoma
December 27, 2013
- MSD Files NDA for Vaniprevir for Chronic Hepatitis C
December 27, 2013
- Kissei Grants US Pfizer Worldwide Exclusive Rights for Gout and Hyperuricemia Treatment KUX-1151 Outside Japan
December 26, 2013
- Meiji Seika Pharma Scraps Codevelopment Deal with Danish Biotech
December 26, 2013
- Takeda to License Inflammatory Bowel Disease Treatment from US Biotech
December 25, 2013
- Tenelia Now Indicated for Type 2 Diabetes Without Concurrent Use Restrictions
December 25, 2013
- SSI Said Ex-Employee Manipulated Data of Anti-Obesity Drug Study
December 25, 2013
- Daiichi Sankyo Files Edoxaban for AF, VTE New Indications
December 25, 2013
- Kyowa Kirin, LEO Pharma Collaborate to Market Fixed-Dose Combination Topical Treatment for Psoriasis in Japan
December 24, 2013
- Shire Names NBI Operating Officer Sunohara as New Japan Head
December 20, 2013
- Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
- Can Epadel Continue to Maintain Sales in the Face of Competition from Lotriga and Generics?
December 20, 2013
- UMN, API, Yakult Conclude Another Joint Biosimilar Business Agreement in Oncology Field
December 19, 2013
- Astellas, Nichi-Iko Conclude Definitive Agreement on Transfer of Fuji Plant
December 19, 2013
- ViiV Healthcare, Shionogi Seal Copromotion Deal for Anti-HIV Treatment Dolutegravir
December 18, 2013
- Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016
December 17, 2013
- Ono Forms Subsidiary in S. Korea, Sets Sights on Anticancer Drug Sales
December 17, 2013
- AstraZeneca Japan to Draw on Overseas Dapagliflozin Data to Trump SGLT-2 Rivals
December 16, 2013
- Pfizer Japan to Reorganize in January with Stand-Alone Vaccines Unit
December 16, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…